Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Timoprazole SCHEMBL563458 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| Timoprazole SCHEMBL9247237 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| Timoprazole SCHEMBL11245124 | 0.99 | CYP1A2 (0.50) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| Timoprazole SCHEMBL9244884 | 0.99 | CYP1A2 (0.50) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL8138606 | 0.86 | CYP1A2 (0.49) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL11373497 | 0.85 | KDM4E (0.48) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL27858001 | 0.84 | METAP1 (0.46) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL6872775 | 0.84 | CBFB (0.51) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL6877256 | 0.84 | ALDH1A1 (0.40) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL6440386 | 0.84 | CBFB (0.40) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1603 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3965735-A1 | PHARMACEUTICAL FORMULATION | Alkaloid AD Skopje (MK) | 2022-03-16 | — | — | EP | claimed |
| US-20210205270-A1 | DRUG COMPOSITIONS | FIRST-CITIZENS BANK & TRUST COMPANY, AS ADMINISTRATIVE AGENT | 2021-07-08 | — | — | US | claimed |
| WO-2020224936-A1 | PHARMACEUTICAL FORMULATION | ALKALOID AD SKOPJE (MK) | 2020-11-12 | — | — | WO | claimed |
| EP-3720844-A1 | DRUG COMPOSITIONS | Adamis Pharmaceuticals Corporation (US) | 2020-10-14 | — | — | EP | claimed |
| WO-2019113493-A1 | DRUG COMPOSITIONS | ADAMIS PHARMACEUTICALS CORPORATION (US) | 2019-06-13 | — | — | WO | claimed |
| US-10130618-B2 | Pharmaceutical combinations of dabigatran and proton pump inhibitors | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2018-11-20 | — | — | US | claimed |
| CN-107698515-A | A kind of preparation method of benzimidazole complex compound | 拉萨泰达医药科技有限公司 | 2018-02-16 | — | — | CN | claimed |
| EP-2521531-B1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-07-12 | — | — | EP | claimed |
| US-20170035745-A1 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND PROTON PUMP INHIBITORS | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2017-02-09 | — | — | US | claimed |
| US-20170035672-A1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-02-09 | — | — | US | claimed |
| EP-0332647-A1 | NEW BENZIMIDAZOLE DERIVATIVES A PROCESS FOR PRODUCTION THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Aktiebolaget Hässle (SE) | 1989-09-20 | — | — | EP | claimed |
| EP-0279149-A2 | Benzimidazole derivatives, process for their production and a pharmaceutical composition containing the same | Aktiebolaget Hässle (SE) | 1988-08-24 | — | — | EP | claimed |
| WO-1988003921-A1 | NEW BENZIMIDAZOLE DERIVATIVES A PROCESS FOR PRODUCTION THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Aktiebolaget Hässle (SE) | 1988-06-02 | — | — | WO | claimed |
| EP-0045200-B1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | THE UPJOHN COMPANY (US) | 1988-03-02 | — | — | EP | claimed |
| EP-0233284-A1 | PHARMACOLOGICAL COMPOUNDS. | HAESSLE AB (SE) | 1987-08-26 | — | — | EP | claimed |
| WO-1987002668-A1 | NOVEL PHARMACOLOGICAL COMPOUNDS | Aktiebolaget Hässle (SE) | 1987-05-07 | — | — | WO | claimed |
| EP-0221041-A2 | Benzimidazole derivatives, process for their preparation and their pharmaceutical use | Aktiebolaget Hässle (SE) | 1987-05-06 | — | — | EP | claimed |
| US-4359465-A | HETEROCYCLIC ALKYLSULFINYL BENZIMIDAZOLES | THE UPJOHN COMPANY (US) | 1982-11-16 | — | — | US | claimed |
| EP-0045200-A1 | Benzimidazoles and their pharmaceutical use | THE UPJOHN COMPANY (US) | 1982-02-03 | — | — | EP | claimed |
| US-4045563-A | Substituted 2-[pyridylalkylenesulfinyl]-benzimidazoles with gastric acid secretion inhibiting effects | AB HASSLE (SW) | 1977-08-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035745-A1 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND PROTON PUMP INHIBITORS | ABCB11, SLC9A5, SLC9A3 | CYP1A2 216/4885CYP2E1 454/4885CYP2C8 308/4885 |
| US-20170035672-A1 | SKIN LIGHTENING COMPOSITIONS | CUTA, TYR, DSG1 | CYP1A2 1093/4885CYP2E1 2659/4885CYP2C8 3954/4885 |
| US-10130618-B2 | Pharmaceutical combinations of dabigatran and proton pump inhibitors | ABCB11, SLC9A5, SLC9A3 | CYP1A2 216/4885CYP2E1 454/4885CYP2C8 308/4885 |
| US-20210205270-A1 | DRUG COMPOSITIONS | CYP2C19, CYP2D6, CYP2B6 | CYP1A2 23/4885CYP2E1 19/4885CYP2C8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.